Omnicell, Inc. (OMCL) Stock Price & How to Invest

Last updated November 2026

Short answer

You can invest in Omnicell (OMCL) by buying shares or fractional shares at any major broker, through a healthcare or medtech ETF that holds it, or as one holding in a thematic basket. Omnicell is a healthcare-technology company that sells medication-management automation (automated dispensing cabinets, robotics, and software) to hospitals and pharmacies, and the investment picture centers on its shift toward recurring subscription and cloud revenue after a post-pandemic slowdown.

OMCL stock price

As of 2026-11-20, Omnicell, Inc. (OMCL) last closed at $32.51, down 9.7% over the past year. Over the past 52 weeks it has traded between $32.23 and $51.39.

OMCL last close
$32.51
1 day
-2.02%
1 month
-10.54%
1 year
-9.69%
52-week range
$32.23 to $51.39
Last close
2026-11-20

Prices are daily closing prices from Yahoo Finance and may be delayed. For the live quote, check your broker or Omnicell, Inc.'s investor relations page. Walnut is informational, not investment advice.

OMCL key stats

At $32.51 on November 20, 2026, Omnicell, Inc. (OMCL) has a market cap of $1.5B and a P/E of 33.9 on trailing earnings (16.2 on forward earnings).

Market cap
$1.5B
P/E (trailing)
33.9
P/E (forward)
16.2
EPS (trailing 12 months)
$0.96
Price to book
1.1
Beta
0.89

Market cap, P/E and yield are measured at the $32.51 price on November 20, 2026, from Yahoo Finance figures pulled in November 2026. Earnings date from Yahoo Finance. Walnut is informational, not investment advice.

What's new with Omnicell, Inc. (OMCL)?

The last two weeks for Omnicell, Inc., as of November 22, 2026: the price move, the next earnings date, what the company filed with the SEC, and what analysts changed.

  • OMCL closed at $32.51 on November 20, 2026, down 7.2% over the past five trading days (from $35.03).

Omnicell, Inc. filed no current, quarterly or annual report with the SEC in the last two weeks.

Prices are daily closes from Yahoo Finance. Filings are read from SEC EDGAR every six hours. Analyst actions come from Yahoo Finance as of November 2026. Walnut is informational, not investment advice.

Omnicell, Inc. (OMCL) latest quarter

Omnicell reported revenue of $308 million for Q3 2026, down 1% from a year earlier (Omnicell, Oct 29, 2026).

Revenue
$308 million
down 1% from a year earlier
Diluted EPS (GAAP)
$0.24
up 100% from a year earlier
Product revenues
$173 million
down 3% from a year earlier

Source: Omnicell Q3 2026 results, Oct 29, 2026. Full earnings breakdown

What does Omnicell, Inc. (OMCL) do?

Omnicell, Inc. (NASDAQ: OMCL) is a healthcare-technology company that builds medication-management and pharmacy-automation systems for hospitals, health systems, retail and specialty pharmacies, and other care settings. Its core products include automated dispensing cabinets (the XT and XR series), central-pharmacy robotics, IV compounding automation, and a growing layer of cloud software and services branded around what the company calls the Autonomous Pharmacy. Omnicell earns money from product sales (the hardware and installed systems) and from a rising base of recurring service and subscription revenue, including its Advanced Services and technician-enabled offerings, and it tracks annual recurring revenue (ARR) and product bookings as key operating metrics.

The investment picture is a turnaround-and-transition story. After a pandemic-era boom and a subsequent slump in hospital capital spending, Omnicell has been steering its mix toward higher-margin recurring revenue while stabilizing its hardware business. Full-year 2025 revenue was about $1.185 billion, up roughly 7% from 2024, with non-GAAP EBITDA of about $140 million, and the company guided 2026 revenue toward roughly $1.215 billion to $1.255 billion. Revenue has since run at a steady clip of about $308 million to $312 million a quarter, putting trailing twelve-month revenue near $1.24 billion as of September 2026. The second quarter of 2026 brought revenue of about $312 million, up roughly 7.5% from a year earlier, and non-GAAP EPS of $0.94 against a consensus of about $0.47. The third quarter, reported October 29, was softer on the top line: revenue of about $308 million was down about 0.9% from a year earlier, GAAP net income was about $11 million, and non-GAAP EPS of $0.58 still beat a $0.42 consensus, the third beat in a row. The company guided fourth-quarter revenue to $295 million to $301 million and full-year 2026 revenue to $1.225 billion to $1.231 billion, the lower half of its original range. The stock has kept sliding: at about $32.61 on November 20, 2026 it was down roughly 28% year to date, about 14% over the past month and about 5% from a year earlier, near the bottom of its 52-week range. The bull case rests on ARR growth, expanding margins, and a large installed base of hospital customers; the bear case reflects reliance on cyclical hospital capital budgets, competition from larger rivals, and a GAAP earnings base that has been depressed relative to the share price.

What's driving Omnicell, Inc. (OMCL)?

1. Shift toward recurring software and services.

Omnicell is steering its revenue mix away from one-time hardware sales toward recurring subscription, cloud, and Advanced Services revenue, which it tracks through annual recurring revenue (ARR). Recurring revenue tends to be higher-margin and more predictable than lumpy capital-equipment sales. Continued growth in ARR and the attach rate of software to installed cabinets is central to the company's margin-expansion story.

2. Large installed base and replacement cycle.

Omnicell has a deep footprint of automated dispensing cabinets and pharmacy systems across US hospitals and health systems, which creates recurring service revenue and upgrade or replacement opportunities as older equipment ages. That installed base is a switching-cost moat because ripping out medication-management infrastructure is disruptive for a hospital. New product cycles and expansion into outpatient, retail, and specialty pharmacy settings widen the addressable market.

3. Recovering hospital capital spending and bookings.

After a slump in hospital capital budgets following the pandemic boom, Omnicell has pointed to stabilizing and recovering product bookings, which are a leading indicator of future revenue. Quarterly revenue has held near $310 million through 2026, but growth faded from about 7.5% in the second quarter to a slight decline of about 0.9% in the third, and guidance of $295 million to $301 million for the fourth quarter implies a softer finish. Analysts expect full-year 2026 revenue of roughly $1.23 billion and about $1.24 billion in 2027, so a sustained recovery in health-system capital spending, which would support both the hardware and the attached-software businesses, is not yet in consensus numbers.

4. Margin and profitability improvement.

Management has focused on cost discipline and mix shift to lift profitability. Non-GAAP EPS was about $0.55 in the first quarter of 2026, $0.94 in the second and $0.58 in the third, against estimates of roughly $0.33, $0.47 and $0.42, and GAAP net income was about $11 million, $24 million and $11 million across those quarters. Analysts now model 2026 EPS near $2.48, falling to about $2.01 in 2027. GAAP margins remain thin (an operating margin near 5% and a net margin near 4% on a trailing basis), so whether the gains turn into durable GAAP earnings is still the key watch item. Trailing free cash flow of about $136 million is well above GAAP net income.

What are the risks to Omnicell, Inc. (OMCL)?

Omnicell's product revenue depends heavily on hospital and health-system capital budgets, which are cyclical and can be cut quickly when providers face financial pressure, making bookings and revenue lumpy. It competes against larger and better-capitalized rivals, most notably BD (Becton Dickinson) with its Pyxis dispensing line, along with Baxter, Swisslog, and other automation vendors, which can pressure pricing and market share. The company's GAAP profitability has at times been thin relative to its share price, so a large gap between GAAP and non-GAAP earnings and a high trailing P/E leave little room for execution missteps. Coverage of the second-quarter report focused on a revenue beat paired with weaker EBITDA guidance, the third quarter showed a small year-over-year revenue decline, and consensus for the next two quarters implies EPS well below the first-half run rate, with 2027 EPS expected to fall about 19%, so the earnings trajectory may look uneven in the near term. Long installation and implementation cycles, customer concentration among big health systems, and integration risk from acquisitions add operational uncertainty. Broader healthcare-policy shifts, reimbursement pressure, supply-chain costs, and any product-reliability or regulatory issues around medication safety could also weigh on results.

What is the Omnicell, Inc. (OMCL) forecast?

7 analysts publish price targets on OMCL, averaging $57.43 as of November 2026, or +76.7% against the $32.51 share price on November 20, 2026. The published targets run from $50.00 to $68.00, a moderate spread, and the ratings split 7 buy, 1 hold, 0 sell. Over the last six months there have been 0 raises and 4 cuts among the published actions. A price target is what an analyst published on a date, not a prediction, and sell-side ratings skew positive across the whole market.

Read the full OMCL forecast and price target for the target table, the recent rating actions by firm, and how the consensus has shifted.

Is OMCL a buy or a sell?

We give no verdict on Omnicell, Inc.. Both cases are real, which is why the question is contested at all, so here is the strongest version of each.

The case for buying. Shift toward recurring software and services. Omnicell is steering its revenue mix away from one-time hardware sales toward recurring subscription, cloud, and Advanced Services revenue, which it tracks through annual recurring revenue (ARR). The most optimistic published target, $68.00, assumes this works close to its best case.

The case against. Omnicell's product revenue depends heavily on hospital and health-system capital budgets, which are cyclical and can be cut quickly when providers face financial pressure, making bookings and revenue lumpy. The most pessimistic target, $50.00, is roughly what OMCL is worth if this bites instead.

Read the full bull and bear case on OMCL, including what would have to change to break either one. Walnut is not an investment adviser.

Has Omnicell, Inc. (OMCL) split its stock?

No. Omnicell, Inc. (OMCL) has not split its stock in the last 10 years. The statement covers only the window we check, so an older split in the company’s history is possible. It also matters less than it once did: fractional shares mean a high price per share no longer keeps smaller investors out, which removed most of the practical reason to split.

How is Omnicell, Inc. (OMCL) valued?

Market cap, P/E and dividend yield at today's price are in the OMCL key stats above. The business figures below come from Omnicell, Inc.'s reported results as of November 2026 and change when it next reports.

  • Revenue (TTM): ~$1.24 billion (Q3 2026 down ~0.9% YoY)
  • Revenue (Q3 2026): ~$308 million
  • 2026 revenue guidance: ~$1.225-1.231 billion
  • Net Income (TTM): ~$45 million (net margin ~3.6%)
  • Cash / Debt: ~$315 million / ~$201 million

As of November 2026: Omnicell trades around $32.61 per share for a market capitalization near $1.5 billion as of November 20, 2026, about 1.2 times trailing sales and roughly 16 times forward earnings, with analysts' mean target near $57. The trailing GAAP P/E of about 34 is far above the forward multiple because GAAP earnings remain small, so the gap between GAAP and non-GAAP profitability is still central to how different investors value the name. Net cash of roughly $114 million and trailing free cash flow near $136 million give the balance sheet some cushion.

Who competes with Omnicell, Inc. (OMCL)?

Large medtech and dispensing rivals

BD (Becton Dickinson) is Omnicell's chief competitor in hospital automated dispensing through its Pyxis line, backed by far larger scale, R&D budgets, and global distribution; its Parata Systems acquisition also strengthened its retail and outpatient pharmacy reach. Baxter competes in IV compounding and medication safety, pressuring Omnicell on integrated inpatient medication management.

Pharmacy-automation and robotics specialists

Swisslog Healthcare competes in central-pharmacy robotics and medication transport automation (products like PillPick and BoxPicker), while firms such as ARxIUM, Capsa Healthcare, and ICU Medical offer dispensing, packaging, and automation systems. These specialists compete on logistics efficiency and niche or regional hospital deployments.

Pharmacy software and health-IT platforms

As Omnicell shifts toward cloud software and the Autonomous Pharmacy vision, it increasingly overlaps with pharmacy-management and health-IT software vendors and with the electronic-health-record ecosystems (such as those tied to Oracle Health and Epic workflows) that hospitals use to manage medication data and interoperability.

What stocks are similar to Omnicell, Inc. (OMCL)?

Other names that sit close to OMCL: same theme, named as a direct competitor, or held beside it in the same funds. Each entry says which. They are useful if you want to spread one thesis across several tickers.

How to invest in Omnicell, Inc. (OMCL)

There are three common ways to get OMCL exposure. Buy shares (or fractional shares) directly at any major broker. Hold an ETF that includes it, which spreads the position across many companies. Or build it into a focused thematic portfolio, so OMCL sits alongside other stocks that express the same thesis.

Walnut takes the portfolio route. Describe a thesis where OMCL fits (for example “AI infrastructure” or “dividend-growth large-caps”) and the AI proposes 5 to 6 constituents with target weights. You review the plan and fund it through your own broker when you're ready.

New to this? Start with how to invest in stocks, see how to analyze a stock with AI, or compare the best AI stock analyzers.

The bottom line on Omnicell, Inc. (OMCL)

Omnicell is a small-to-mid-cap pharmacy-automation company working through a transition from lumpy hardware sales toward recurring software and service revenue, with trailing revenue of about $1.24 billion and a market value near $1.5 billion as of November 2026, and it trades and moves like a cyclical, execution-sensitive healthcare-tech name: the shares are down about 28% in 2026 despite three straight quarters of EPS beats, as revenue growth flattened in the third quarter.

More on Omnicell, Inc. (OMCL)

Whether OMCL is worth buying today depends more on your time horizon and what you already hold than on any single call. We walk through valuation, what would have to go right, and the risks in is OMCL a buy or a sell?, and where the stock could go from here in the OMCL stock forecast.

For income investors, whether OMCL pays a dividend and how the payout looks is covered in does OMCL pay a dividend? And to weigh OMCL against a peer, read the full side-by-side comparisons: OMCL vs BAX and OMCL vs ICUI.

Wondering how OMCL fits the portfolio you already own? Walnut is an AI investing app that connects your brokerage read-only and answers questions like that about your actual holdings: overlap, concentration, and how each position tracks the S&P 500. Compare the best AI portfolio analyzers or see the best AI investing apps in 2026.

Your questions about Omnicell, Inc.

Ask Walnut's AI anything about OMCL and see how it fits what you own.

FAQ

What does Omnicell do?

+

Omnicell is a healthcare-technology company that sells medication-management and pharmacy-automation systems, including automated dispensing cabinets, central-pharmacy robotics, IV compounding automation, and cloud software, to hospitals, health systems, and pharmacies. It earns revenue from both hardware sales and a growing base of recurring service and subscription contracts.

Is Omnicell profitable?

+

Omnicell earned about $45 million of GAAP net income on roughly $1.24 billion of trailing revenue as of September 2026, a net margin near 3.6%, and its non-GAAP EPS of $0.55, $0.94 and $0.58 in the first three quarters of 2026 came in ahead of estimates each time. GAAP earnings have been thin for several years, which is why its trailing P/E (about 34) looks high next to its forward P/E (about 16).

How do I buy OMCL stock?

+

OMCL trades on the Nasdaq, so you can buy whole or fractional shares through any major US broker. Some investors also gain exposure indirectly through healthcare or medical-technology ETFs that hold Omnicell, or by including it as one position in a diversified basket.

Does Omnicell pay a dividend?

+

Omnicell has historically not paid a regular cash dividend, instead reinvesting in its business and, at times, repurchasing shares. Investors looking at OMCL are generally focused on revenue growth, margin expansion, and recurring-revenue trends rather than dividend income.

Who are Omnicell's main competitors?

+

Its biggest competitor is BD (Becton Dickinson), whose Pyxis line rivals Omnicell in hospital automated dispensing. Others include Baxter in IV and compounding automation, Swisslog in pharmacy robotics and transport, and specialists such as ARxIUM, Capsa Healthcare, and ICU Medical, plus overlapping health-IT and pharmacy-software platforms.

What is annual recurring revenue (ARR) and why does it matter for Omnicell?

+

ARR measures the annualized value of Omnicell's recurring subscription and service contracts. It matters because the company is trying to shift its mix away from lumpy one-time hardware sales toward higher-margin, more predictable recurring revenue, so ARR growth is a key signal of that transition working.

Why is Omnicell's revenue considered cyclical?

+

A large share of Omnicell's product revenue comes from hospitals and health systems buying capital equipment, and those capital budgets rise and fall with provider finances. When hospitals tighten spending, Omnicell's bookings and hardware revenue can drop quickly, which makes results uneven from quarter to quarter and year to year.

What are the biggest risks to the Omnicell investment case?

+

Key risks include cyclical hospital capital spending, intense competition from larger rivals like BD, a trailing GAAP P/E of about 34 that leaves little room for execution missteps, customer concentration among big health systems, long implementation cycles, and broader healthcare-policy or reimbursement pressures. Any of these could weigh on growth or margins. The stock's roughly 28% decline in 2026, even after three straight EPS beats, shows how sensitive it is to guidance and revenue growth.

How did Omnicell do in its latest quarter?

+

In the third quarter of 2026 (the three months to September 30, reported October 29), Omnicell reported revenue of about $308 million, down roughly 0.9% from a year earlier, GAAP net income of about $11 million, and non-GAAP EPS of $0.58 against a consensus near $0.42. It guided fourth-quarter revenue to $295 million to $301 million and full-year revenue to $1.225 billion to $1.231 billion. The second quarter had brought revenue of about $312 million, up 7.5%, and EPS of $0.94.

How has OMCL stock performed in 2026?

+

As of November 20, 2026, OMCL closed near $32.61, down about 28% year to date, about 14% over the past month and about 5% over the past year. Its 52-week range is roughly $31.75 to $55, so the shares sit near the low end. Walnut is not an investment adviser, and past price moves say nothing certain about future returns.

What is Omnicell's 2026 revenue guidance?

+

With its third-quarter report on October 29, 2026, Omnicell guided full-year 2026 revenue to $1.225 billion to $1.231 billion, within the lower half of the $1.215 billion to $1.255 billion range it set at the start of the year, and fourth-quarter revenue to $295 million to $301 million. That compares with about $1.185 billion of revenue in 2025.

Walnut is informational, not investment advice. Financial figures on this page are approximations; always verify current numbers with Omnicell, Inc.'s investor relations page or your broker before making investment decisions.